Mitral Adjustable Annuloplasty Ring Feasibility and Safety Study

Inclusion Criteria: * Males or females aged greater or equal to 18 to less than or equal to age 75. * Patients with indications to undergo mitral valve repair consistent with ACC/AHA recommendations; including greater or equal to 2+ regurgitation by pre-operative TEE or TTE assessment. * Candidate for cardiopulmonary bypass. * A Left Ventricular Ejection Fraction greater or equal to 40%. * Able and willing to comply with all study requirements, including the required study follow-up visits. * Able and willing to five consent and follow study instructions. * Female patients of childbearing potential (not surgically sterilized or more than one year postmenopausal), with a negative pregnancy test (serum beta-hCG) within 24 hours prior to mitral valve surgery. Exclusion Criteria: * Any previous cardiac surgery. * Any interventional cardiology procedure within six months prior to study to include all patients that have had a drug eluting stent (DES) implanted within 6 months. * Evidence of an acute Myocardial Infarction (MI) within 7 days of the intended treatment with the investigational device. * Prior mitral valve surgery or valvuloplasty or currently implanted prosthetic valve. * Restricted mobility of the mitral apparatus that results in a valvular area less than 3.0 cm2. * Recent or evolving bacterial endocarditis or patients under current antibiotic therapy. * Patients with ICD's. * Any angiographic or clinical evidence that the investigator feels would place the patient at increased risk with the placement of the device or concurrent medical condition with a life expectancy of less than 12 months. * Patients who are immunocompromised or with autoimmune diseases. * Patients suffering from renal insufficiency (Creatinine \>2.5 mg/dL) or patients with chronic renal failure undergoing dialysis. * Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g. sever chronic obstructive pulmonary disease, hepatic failure, immunosuppressive abnormalities, haematological abnormalities). * Significant mitral annular calcification. * Use of Coumadin, IIbIIIa inhibitors, Clopidigrel (Plavix) or other anti-coagulants within (5) five days prior to surgery. * Participation in any study involving an investigational drug or device within the past month, or ongoing participation in a study with an investigational device. * Intolerance or hypersensitivity to anaesthetics. * Patients in whom transesophageal echo/Doppler is contraindicated. * History of bleeding diathesis or coagulopathy. * History of stroke within the prior 6 months * Subjects to undergo concomitant cardiac repair or replacement other than CABG (less than or equal to 3 vessels) mitral annuloplasty, tricuspid valve repair and ablation therapy for correction of atrial fibrillation. Excluded concomitant procedures are: aortic valve replacement, LV remodeling, surgery and congenital repair. * Patients with Euroscore \> 10.